Documents reviewing the research on peptides note lack of good evidence of efficacy or safety. Yet an FDA panel will consider easing access to them later this month.
The level of care necessary to keep a human infant alive is so phenomenal that the continuation of the species is something too few appreciate as a daily miracle.
The world's first human trial of whether a drug can essentially make a person's cells younger sets up a reality check for one of the longevity field's most promising theories. Why it matters: The early-stage clinical trial will signal whether "cellular reprogramming" can be performed safely in humans, a prerequisite for any future claim that a treatment can slow or even reverse biological aging. The big picture: Attempts to prolong the human lifespan can refer to anything from better diet and exercise to the infusion of blood plasma from young donors. - The former is validated by decades of science; the latter has merited two warnings from the Food and Drug Administration that said such treatments lack any evidence of clinical benefit. …
Though electric machines are now standard, the Venezuelan weaver Margarita Mora has clung to a mix of ancestral Indigenous and Spanish practices to create surprisingly modern work.